Study on the Effectiveness and Safety of VRT in Patients With Visual Field Defects

Launched by XUANWU HOSPITAL, BEIJING · Apr 4, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the effectiveness and safety of a treatment called visual restoration therapy (VRT) for people who have visual field defects, which means they have lost some areas of their vision. The main goals of the study are to find out if VRT can help expand the areas of vision that these patients are missing and to understand any medical problems that might occur during the treatment. Participants will be assessed for their vision, provided with helpful vision aids, and will receive VRT sessions three times a week for three months. They will also keep a diary to track any symptoms they experience while undergoing the treatment.

To be eligible for this trial, participants should be between 18 and 80 years old and have a confirmed diagnosis of visual field defects. They should also be in stable health and not at risk of losing more vision during the trial. Importantly, individuals who are blind or have certain other health issues, like severe cognitive impairments, will not be able to participate. Throughout the study, participants will visit the clinic at one and three months after starting the trial to check on their vision and complete a questionnaire about their quality of life related to their vision. This study hopes to provide new insights into how VRT can help improve vision for those affected by visual field defects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Participants with a clear diagnosis of visual field defects.
• • 2. Participants were between 18 and 80 years of age (including borderline values);
• • 3. Participants have been treated for their primary disease and conditions are stable;
• • 4. Participants are not at significant risk of vision loss in the last three months;
• • 5. Participants do not have planned intraocular surgery during the trial period；
• • 6. Participants can understand the trial protocol and sign informed consent.
• Exclusion Criteria:
• • 1. Participants diagnosed as blindness;
• • 2. Participants with a previous history of seizures or other psychiatric disorders;
• • 3. Participants with cognitive impairments;
• • 4. Participant's attention span is less than 30 minutes;
• • 5. Participants had conditions such as significant ptosis or severe dry eye;
• • 6. Participants who were in poor general health or who could not cooperate in completing the study protocol for some reasons such as transport.